SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
pages: 1 2
|
presentations:
1 to
50 of
76
|
THE CHALLENGES OF HIV TREATMENT IN AN ERA OF POLYPHARMACY (ABSTRACT
120)
David Back
University of Liverpool, Liverpool, United Kingdom
NEUROHIV: WHAT THE VIRUS TELLS US (ABSTRACT
121)
Ronald Swanstrom
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
SEARCH INTERVENTION REDUCES MORTALITY AT A POPULATION LEVEL IN MEN WITH LOW CD4 COUNT (ABSTRACT
138)
Moses R. Kamya
Makerere University College of Health Sciences, Kampala, Uganda
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS (ABSTRACT
139)
Susan Swindells
University of Nebraska Medical Center, Omaha, NE, USA
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS (ABSTRACT
140)
Chloe Orkin
Barts Health NHS Trust, London, United Kingdom
SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR (ABSTRACT
141)
Jennifer E Sager
Gilead Sciences, Foster City, CA, USA
A PHASE IIA STUDY OF NOVEL MATURATION INHIBITOR GSK2838232 IN HIV PATIENTS (ABSTRACT
142)
Edwin DeJesus
Orlando Immunology Center, Orlando, FL, USA
SYSTEMATIC DETERMINATION OF IN VITRO HIV-1 INTEGRASE RESISTANCE FROM CLINICAL SAMPLES (ABSTRACT
143)
Aniqa Shahid
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
DTG VS LPV/R (DAWNING): EFFICACY BY BASELINE NRTI RESISTANCE AND SECOND-LINE NRTI USE (ABSTRACT
144)
Dannae Brown
ViiV Healthcare, Surry Hills, NSW, Australia
THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS (ABSTRACT
145)
Kathryn E. Stephenson
Beth Israel Deaconess Medical Center, Boston, MA, USA
HIGH HIV VIRAL BURDEN PERSISTS IN CXCR3+ GCTFH DESPITE VERY EARLY ART INITIATION (ABSTRACT
130)
Zaza Ndhlovu
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
SIROLIMUS REDUCES T-CELL CYCLING AND IMMUNE CHECKPOINT MARKER EXPRESSION, ACTG A5337 (ABSTRACT
131)
Timothy J Henrich
UCSF, San Francisco, CA, USA
PD-1 AND CTLA-4 BLOCKADE IN MACAQUES INDUCES T-CELL EXPANSION AND SIV REACTIVATION (ABSTRACT
132)
Mirko Paiardini
Emory University School of Medicine, Atlanta, GA, USA
FTY720 LIMITS T FOLLICULAR HELPER CELL INFECTION IN LYMPHOID SITES OF SIV PERSISTENCE (ABSTRACT
133)
Maria Pino
Yerkes National Primate Research Center, Atlanta, GA, USA
TRANSCRIPTIONAL SIGNATURE OF LYMPH NODE CD8+ T CELLS IN HIV ELITE CONTROLLERS (ABSTRACT
134)
Son Nguyen
University of Pennsylvania, Philadelphia, PA, USA
CHARACTERIZING THE PROVIRAL LANDSCAPE IN HIV-1 ELITE CONTROLLERS (ABSTRACT
135)
Chenyang Jiang
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
INTERFERON Α2B REDUCES INDUCIBLE CD4-ASSOCIATED HIV IN ART-SUPPRESSED INDIVIDUALS (ABSTRACT
136)
Livio Azzoni
The Wistar Institute, Philadelphia, PA, USA
NEF-STOP REPAIR DYNAMICS, BUT NOT ANTI-Α4Β7, INFLUENCE POSTTREATMENT VIRAL CONTROL (ABSTRACT
137)
Michele Di Mascio
NIAID, Rockville, MD, USA
MORTALITY REDUCTION IN WESTERN KENYA DURING SCALE-UP OF HIV TREATMENT, 2011-2016 (ABSTRACT
146)
Emily C. Zielinski-Gutierrez
US Centers for Disease Control and Prevention, Nairobi, Kenya
OPIOID OVERDOSE DEATHS AMONG PERSONS WITH HIV INFECTION, UNITED STATES, 2011-2015 (ABSTRACT
147)
Karin A. Bosh
Centers for Disease Control and Prevention, Atlanta, GA, USA
EARLY MORTALITY IN HIV-INFECTED PATIENTS INITIATING ART WITHOUT A PRETHERAPY CD4 (ABSTRACT
148)
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
UTILITY OF CD4 CELL COUNT MONITORING IN BOTSWANA: ANALYSIS OF ROUTINE LABORATORY DATA (ABSTRACT
149)
Tshepo Botho Leeme
Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana
TRENDS IN CD4 AND VIRAL LOAD TESTING IN SOUTHERN AFRICA: ANALYSIS OF 6 COUNTRIES (ABSTRACT
150)
Matthias Egger
University of Bern / Switzerland, Bern, Switzerland
HIGH LEVELS OF DRUG RESISTANCE AMONG ART-EXPERIENCED HOSPITALIZED PATIENTS (ABSTRACT
151)
Claire Bossard
Médecins Sans Frontières, Cape Town, South Africa
HIV DRUG RESISTANCE IN SOUTH AFRICA: RESULTS FROM A POPULATION-BASED HOUSEHOLD SURVEY (ABSTRACT
152)
Sizulu Moyo
Human Sciences Research Council, Cape Town, South Africa
DURATION OF INFECTIOUSNESS AMONG PERSONS WITH HIV DIAGNOSED DURING 2012-2016 (ABSTRACT
153)
Nicole Crepaz
Centers for Disease Control and Prevention, Atlanta, GA, USA
BRAIN CONNECTIVITY IN NEUROLOGICALLY ASYMPTOMATIC PEOPLE WITH HIV SWITCHING ART (ABSTRACT
122)
Jaime H Vera
Brighton and Sussex Medical School, University of Sussex, Brighton, East Sussex, United Kingdom
DEEP-LEARNING CEREBRAL BLOOD FLOW FOR COGNITIVE-IMPAIRMENT CLASSIFICATION IN HIV (ABSTRACT
123)
Patrick Luckett
Washington University in St Louis, St Louis, MO, USA
HOST GLYCOMIC DETERMINANTS OF HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING THERAPY (ABSTRACT
124)
Leila Bertoni Giron
The Wistar Institute, Philadelphia, PA, USA
CSF SCD30 ELEVATION DESPITE SUPPRESSIVE ART SUGGESTS CNS HIV PERSISTENCE (ABSTRACT
125)
Michael Peluso
University of California - San Francisco, San Francisco, CA, USA
CSF HIV RNA DETECTED AT <20 COPIES/ML ASSOCIATES WITH BLOOD-BRAIN BARRIER MEASURES (ABSTRACT
126)
Shelli Farhadian
Yale School of Medicine, New Haven, CT, USA
EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF (ABSTRACT
127)
Linn Hermansson
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
CARDIOVASCULAR RISK SCORES PREDICT LONGITUDINAL COGNITIVE FUNCTION IN OLDER PLHIV (ABSTRACT
128)
Felicia C Chow
UCSF, San Francisco, CA, USA
OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV (ABSTRACT
129)
Kristine M Erlandson
University of Colorado, Aurora, CO, USA
THEMED DISCUSSION LEADER
Alan Winston
Imperial College London, London, United Kingdom
NEUROPSYCHIATRIC OUTCOMES BEFORE AND AFTER SWITCHING TO DOLUTEGRAVIR-BASED THERAPY (ABSTRACT
440)
Phillip Chan
SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
NEUROPSYCHOLOGICAL CHANGES IN EFAVIRENZ SWITCH REGIMENS IN MACS (ABSTRACT
441)
Yijia Li
University of Pittsburgh, Pittsburgh, PA, USA
MEMORY AND LEARNING DYSFUNCTION WITH INTEGRASE STRAND TRANSFER INHIBITORS USE (ABSTRACT
442)
Jane A O'Halloran
Washington University in St Louis, St Louis, MO, USA
CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR (ABSTRACT
443)
Borja Mora-Peris
Imperial College London, London, United Kingdom
CENTRAL NERVOUS SYSTEM EFFECTS OF THERAPY INITIATION WITH INTEGRASE INHIBITORS (ABSTRACT
439)
Jose A. Muñoz-Moreno
Lluita contra la SIDA Foundation - Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
THEMED DISCUSSION LEADER
Debika Bhattacharya
University of California Los Angeles, Los Angeles, CA, USA
HEPATITIS B CURE IN HIV PATIENTS IS MORE LIKELY IN HISPANICS AND THOSE WITH AIDS (ABSTRACT
624)
Mamta K Jain
University of Texas Southwestern Medical Center, Dallas, TX, USA
HIGH RATES OF HBV FUNCTIONAL CURE AMONG HIV/HBV-COINFECTED PATIENTS ON ART IN ZAMBIA (ABSTRACT
625)
Belinda Varaidzo Chihota
Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia
HEPATITIS B VIROLOGIC FAILURE OF TENOFOVIR-BASED THERAPIES IN PATIENTS WITH HIV/HBV (ABSTRACT
626)
Meredith Mock
Duke University, Durham, NC, USA
HIV LATE PRESENTATION AND ITS IMPACT ON HBV SEROCONVERSION IN HBV/HIV (ABSTRACT
627)
Christoph Boesecke
University Hospital Bonn, Bonn, Germany
ABSENCE OF HBV REACTIVATION IN HIV/HCV/HBCAB COINFECTED PATIENTS TREATED WITH DAA (ABSTRACT
628)
Maddalena Cerrone
Chelsea and Westminster Hospital NHS Trust, London, UK, London, United Kingdom
THEMED DISCUSSION LEADER
James A. McIntyre
Anova Health Institute, Johannesburg, South Africa
CHANGES IN KIDNEY FUNCTION AMONG MSM INITIATING ON-DEMAND TDF/FTC FOR HIV PREP (ABSTRACT
960)
Geoffroy Liegeon
AP-HP, Hopital Saint Louis, Paris, France
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
pages: 1 2
|
presentations:
1 to
50 of
76
|